Clinical trials: Metastatic Solid Tumor Cancer
Pancreatic Cancer, Breast Cancer
Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors
Study of NGM831 as Monotherapy and in Combination with Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors
- Conditions
- Pancreatic Cancer, Breast Cancer, Gastric Cancer, Non-small Cell Lung Cancer
- Trial name
- NCT05215574
- Testing
- NGM831, NGM831 plus pembrolizumab (KEYTRUDA®), NGM831 and NGM438 plus pembrolizumab (KEYTRUDA®)
- Where
- 9 sites in United States
- Volunteers
- 130 people
- Sponsor
- NGM Biopharmaceuticals, Inc
Unspecified Adult Solid Tumor, Protocol Specific
SJG-136 in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed By Surgery
This phase I trial studies the side effects and best dose of SJG-136 in treating patients with solid tumors that are metastatic or cannot be removed by surgery.
- Trial name
- NCT00121290
- Testing
- SJG-136, laboratory biomarker analysis, pharmacological study
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- National Cancer Institute (NCI)
Unspecified Adult Solid Tumor, Protocol Specific
1-Methyl-D-Tryptophan in Treating Patients With Metastatic or Refractory Solid Tumors That Cannot Be Removed By Surgery
This phase I trial is studying the side effects and best dose of 1-methyl-D-tryptophan in treating patients with metastatic or refractory solid tumors that cannot be removed by surgery.
- Trial name
- NCT00567931
- Testing
- 1-methyl-d-tryptophan, pharmacological study, laboratory biomarker analysis
- Where
- 2 sites in United States
- Volunteers
- 52 people
- Sponsor
- National Cancer Institute (NCI)
Diffuse Pleural Mesothelioma, Gastroesophageal Carcinoma
A Study of BMS-986504 With Standard-of-Care Therapy for People With Solid Tumor Cancer
The researchers are doing this study to test the safety of BMS-986504 in combination with standard disease-specific anticancer medication in people with metastatic/advanced unresectable MTAP-deleted solid tumor cancer.
- Conditions
- Diffuse Pleural Mesothelioma, Gastroesophageal Carcinoma, Urothelial Carcinoma
- Trial name
- NCT07532902
- Testing
- BMS-986504, Ipilimumab, Nivolumab
- Where
- 7 sites in United States
- Volunteers
- 60 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Leptomeningeal Metastasis
Circulating Tumor DNA in Cerebrospinal Fluid as an Early Biomarker of Leptomeningeal Metastasis (LM)
The purpose of this study is to learn whether the DNA from cancer tumor cells can be found in the cerebral spinal fluid (CSF) that bathes the brain and spinal cord of patients before malignant the cancer cells themselves are able…
- Trial name
- NCT02071056
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Advanced Solid Tumor, Metastatic Solid Tumor
PRT3789 Monotherapy and in Combo w/Docetaxel in Participants w/Advanced or Metastatic Solid Tumors w/SMARCA4 Mutation
This is a Phase 1 dose-escalation study of PRT3789, a SMARCA2 degrader, in participants with advanced or metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion.
- Conditions
- Advanced Solid Tumor, Metastatic Solid Tumor, Non-small Cell Lung Cancers, SMARCA4 Gene Mutation
- Trial name
- NCT05639751
- Testing
- PRT3789, Docetaxel
- Where
- 32 sites in United States, France and 3 more
- Volunteers
- 135 people
- Sponsor
- Prelude Therapeutics Incorporated
Triple Negative Breast Cancer, Diffuse Large B Cell Lymphoma
A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.
A phase 1, multicenter, open label, non-randomized dose escalation and dose expansion study to examine the maximum tolerated dose, (MTD), minimum effective dose (MED) and/or recommended dose for expansion (RDE) of intratumoral…
- Conditions
- Triple Negative Breast Cancer, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Lymphoma, Non-Hodgkin
- Trial name
- ON-5001 (NCT06022029)
- Testing
- ONM-501, Cemiplimab
- Where
- 16 sites in United States, Australia
- Volunteers
- 168 people
- Sponsor
- OncoNano Medicine, Inc.
Neoplasm Metastasis
A Study of Pembrolizumab in Combination With Investigational Agents in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01B/LIGHTBEAM-U01)
This study is a rolling arm study of pembrolizumab in combination with investigational agents in pediatric participants with relapsed or refractory classical Hodgkin lymphoma (cHL) solid tumors with microsatellite…
- Trial name
- NCT06395090
- Testing
- Pembrolizumab, Favezelimab, Favezelimab/Pembrolizumab
- Where
- 12 sites in United States, South Korea and 1 more
- Sponsor
- Merck Sharp & Dohme LLC
Recurrent Colon Cancer, Liver Metastases
Isolated Hepatic Perfusion With Melphalan Followed By Chemotherapy in Treating Patients With Unresectable Colorectal Cancer That is Metastatic to the Liver
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug and giving them in different ways may kill more tumor cells.
- Conditions
- Recurrent Colon Cancer, Liver Metastases, Stage IV Rectal Cancer, Recurrent Rectal Cancer
- Trial name
- NCT00019760
- Testing
- floxuridine, leucovorin calcium, melphalan
- Where
- United States
- Sponsor
- National Institutes of Health Clinical Center (CC)
Brain and Central Nervous System Tumors, Gastrointestinal Carcinoid Tumor
Radiolabeled Octreotide in Treating Children With Advanced or Refractory Solid Tumors
RATIONALE: Radiolabeled octreotide can locate tumor cells and deliver radioactive tumor-killing substances to them without harming normal cells.
- Conditions
- Brain and Central Nervous System Tumors, Gastrointestinal Carcinoid Tumor, Islet Cell Tumor, Neuroblastoma
- Trial name
- NCT00049023
- Testing
- 90Y-DOTA-tyr3-OCTREOTIDE
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- O'Dorisio, M S
Solid Tumor
Study of SHR2150 (TLR7 Agonist) in Combination With Chemotherapy Plus PD-1 or CD47 Antibody in Subjects With Unresectable/ Metastatic Solid Tumors
This phase I/II trial aims to evaluate safety and efficacy of SHR2150 in combination with chemotherapy plus PD-1 or CD47 antibody in subjects with unresectable/ metastatic solid tumors.
- Trial name
- NCT04588324
- Testing
- SHR2150, Anti-Cancer Agent
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Chinese PLA General Hospital
Male Breast Cancer, Recurrent Adenoid Cystic Carcinoma of the Oral Cavity
Alvespimycin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors
This phase I trial is studying the side effects and best dose of alvespimycin hydrochloride in treating patients with metastatic or unresectable solid tumors.
- Conditions
- Male Breast Cancer, Recurrent Adenoid Cystic Carcinoma of the Oral Cavity, Recurrent Basal Cell Carcinoma of the Lip, Recurrent Breast Cancer
- Trial name
- NCT00089362
- Testing
- alvespimycin hydrochloride, laboratory biomarker analysis, pharmacological study
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
Solid Cancers
A Study of the Safety and Pharmacology of MEGF0444A in Combination With Bevacizumab With or Without Paclitaxel in Patients With Locally Advanced or Metastatic Solid Tumors
This is a Phase Ib, open-label, dose-escalation study of MEGF0444A in combination with bevacizumab, and in combination with bevacizumab and paclitaxel as therapy for locally advanced or metastatic solid tumors.
- Trial name
- NCT01075464
- Testing
- MEGF0444A, bevacizumab, paclitaxel
- Where
- 5 sites in United States
- Volunteers
- 64 people
- Sponsor
- Genentech, Inc.
Carcinoma, Non Small Cell Lung, Carcinoma, Pancreatic Ductal
A Clinical Trial of PF-08046037 Alone or With Sasanlimab in Patients With Advanced or Metastatic Malignancies
The purpose of this study is to learn about the safety and the effects of PF-08046037 alone or with sasanlimab for the treatment of certain advanced or metastatic malignancies.
- Conditions
- Carcinoma, Non Small Cell Lung, Carcinoma, Pancreatic Ductal, Malignant Melanoma, Squamous Cell Carcinoma of the Head and Neck (SCCHN)
- Trial name
- NCT06974734
- Testing
- PF-08046037, sasanlimab
- Where
- 15 sites in United States, Puerto Rico
- Volunteers
- 8 people
- Sponsor
- Pfizer
Advanced Cancer
Phase 1/2 Study of UI-102 in Selected Advanced Cancers
This phase 1/2 first-in-human study is designed to assess the safety and efficacy of UI-102, a TLR7/8 agonist encapsulated in a Cholesteryl Pullulan Nanoparticle.
- Trial name
- NCT07605962
- Testing
- UI-102
- Where
- 3 sites in United States
- Volunteers
- 140 people
- Sponsor
- United Immunity, co., Ltd.
Locally Advanced Solid Tumors
A Phase I Study of SIM0686 in Participants With Locally Advanced/Metastatic Solid Tumors
This is an open-label, multicenter phase 1 study to evaluate the safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of SIM0686 in Adult Participants with Locally Advanced/Metastatic Solid Tumors
- Trial name
- NCT07050459
- Testing
- SIM0686
- Where
- 10 sites in China
- Volunteers
- 220 people
- Sponsor
- Jiangsu Simcere Pharmaceutical Co., Ltd.
Solid Tumor, Gastric Cancer
SON-DP in Participants With Relapsed/Refractory Intolerant to Standard of Care Therapies for Advanced/Metastatic Solid Tumors
A Phase I Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of SON-DP in Subjects with Advanced Solid Tumors
- Conditions
- Solid Tumor, Gastric Cancer, Liver Cancer
- Trial name
- NCT06873659
- Testing
- SON-DP
- Where
- 11 sites in China
- Volunteers
- 96 people
- Sponsor
- Qurgen Inc.
Cervical Cancer, Chronic Myeloproliferative Disorders
Dalteparin to Prevent Complications in Cancer Patients Receiving Chemotherapy Through a Catheter
RATIONALE: The use of dalteparin may be able to prevent complications caused by the use of a catheter to supply chemotherapy to cancer patients. It is not yet known if dalteparin is effective in reducing these complications.
- Conditions
- Cervical Cancer, Chronic Myeloproliferative Disorders, Leukemia, Lymphoma
- Trial name
- NCT00006083
- Testing
- Fragmin
- Where
- United States
- Sponsor
- Jonsson Comprehensive Cancer Center
Anemia, Carcinoma, Non-Small-Cell Lung
To Determine Safe and Effective Dose of Sotatercept for the Treatment of Chemotherapy Induced Anemia in Participants With Advanced Non-small Cell Lung Cancer
The purpose of this study was to determine an effective and safe dose of sotatercept (ACE-011) for the treatment of chemotherapy-induced anemia (CIA) in participants with metastatic non-small cell lung cancer (NSCLC) who are…
- Conditions
- Anemia, Carcinoma, Non-Small-Cell Lung, Carcinoma, Small-Cell Lung, Bladder Cancer
- Trial name
- NCT01284348
- Testing
- Sotatercept 15 mg, Sotatercept 30 mg
- Volunteers
- 26 people
- Sponsor
- Merck Sharp & Dohme LLC
Advanced Solid Tumors
A Study of ASP2074 in Adults With Solid Tumors
ASP2074 is a potential new treatment for people with certain solid tumors. Before ASP2074 is available as a treatment, the researchers need to understand how it is processed by and acts upon the body.
- Trial name
- NCT05646797
- Testing
- ASP2074
- Where
- 13 sites in United States, Japan
- Volunteers
- 23 people
- Sponsor
- Astellas Pharma Global Development, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.